Key Updates on Renal Cell Carcinoma Treatments from ASCO

This chapter delves into key findings from the ASCO Annual Meeting regarding renal cell carcinoma treatments, emphasizing the survival benefits of adjuvant pembrolizumab from the Keynote 564 trial. It also explores long-term responses from the Checkmate 214 trial and addresses important data from the Pedigree trial, including patient dropout rates and therapy side effects.